Biovica's Pharma-Services Turn Is Real. The Dilution Is the Catch.

A 56% top-line growth print, a division that nearly doubled, and a stock that has still lost close to half its value over the past year. On its face, the first quarter from Swedish diagnostics maker Biovica International looks like the upturn investors in this beaten-down name have waited years for. The fair reading is that the growth is mostly genuine. The catch is how tiny the base is — and how the company is paying for the road to something bigger.

Biovica is not a story most U.S. retail investors carry around. It is a microcap blood-test maker whose DiviTum TKa assay — an FDA-cleared, CE-marked test that measures cell proliferation to track cancer progression, mainly in metastatic breast cancer — is listed on Sweden's Nasdaq First North and also traded in Frankfurt as STU:9II. It does not report in dollars and it does not trade like a U.S. story. What it shares with the setup worth watching is an expectations reset: the market has knocked the stock down roughly 48% over twelve months, to SEK 0.31 and a market capitalization near SEK 90 million, while management claims the operations underneath are getting cleaner.

The surge, sized correctly

In the quarter ending July 2026, net sales came to SEK 4.0 million, up 56% from a year earlier. Nearly all of that drive came from one place. Pharma Services — the division that runs DiviTum TKa as contract biomarker testing for drugmakers in clinical development — grew about 95%, and within it, the Pharma Test piece rose 187%. Management points to a ninth work order from a leading global pharmaceutical customer, an expanded master-services agreement, and fresh orders from clinical-stage oncology companies developing next-generation CDK inhibitors.

Now lay the growth rate next to the base it grew from. Total revenue for the quarter was SEK 4.0 million — roughly US$400,000 — and Pharma Services now accounts for the clear majority of it. The surge is real, but it is a surge measured in a puddle, not a river. What matters more than the number is what it signals: the company has found customers who pay it, repeatedly, for a validated biomarker, and the work is recurring rather than one-off.

The old story is dead, on purpose

That longevity is worth understanding, because it explains why this pivot is not just a marketing shift. Biovica's original plan was to sell DiviTum TKa directly into U.S. oncology as a commercial diagnostic, with Tempus AI as a distribution partner in an agreement announced in May 2025. More than a year later the deal had produced no commercial launch and no revenue, and in late June 2026 Biovica terminated it by mutual agreement, redirecting resources toward channels with a clearer path to near-term adoption. It also cut EU distribution and took SEK 2.2 million in restructuring charges to make the organization leaner.

That is a reset from the easy-to-tell story — a giant addressable market of about US$3 billion — to a humbler one: do contract work pharma will actually pay for from the San Diego lab, and let the clinical evidence accrue on the side. It is the kind of simplification that can justify a rerating, provided the simplified business can actually scale.

The denominator is doing the arguing

Here is the discipline part, because this is where a pre-profit microcap separates a business story from an investment story. Biovica has no free cash flow to point to — it is burning roughly SEK 16 million a quarter in operations against quarterly sales of SEK 4 million — and it is funding that gap with dilution. The share count roughly tripled over the year, to about 292 million, and the board has just proposed another fully guaranteed rights issue: SEK 29.2 million at SEK 0.30 a share, roughly a 23% discount to the theoretical ex-rights price, mostly underwritten by its largest holder. Add that to the SEK 51.6 million on hand and the runway stretches to about five quarters at the current burn.

The honest reading is that Biovica now has the thing worth looking for — an improving operating path with a concrete proof point in Pharma Services — layered on top of the thing not to hand-wave: a company that still needs recurring capital infusions to survive to the point where the growth matters. A depressed valuation is not, on its own, evidence of an opportunity; it can just as easily price permanent deterioration. Here the operative question is whether Pharma Services can compound from the majority of a SEK 4 million quarter into a revenue base that pushes back against a SEK 16 million burn — and whether the dilution stops growing faster than the revenue does.

The break condition is specific. If the backlog keeps winning orders but those orders stop converting into a materially larger income statement — or if the cash window keeps being refilled by rights issues that dilute faster than the emerging revenue compounds — this is a well-run retreat, not a turn. The proof path is the reverse: Pharma Services keeps compounding at a multiple of its cost base, and the operating loss keeps shrinking without a fresh raise.

I can be wrong here, and not just about timing. The base is small, the funding is dilutive, and there is no cash-flow bridge to hide behind yet. What is harder to dismiss is direction: the market is still pricing the old, failed diagnostic story while the operating setup — a real, recurring Pharma Services customer base and a leaner cost structure — is getting cleaner. That is not yet a buy thesis. It is a reason to keep watching whether the surge is still a puddle or becoming a stream.